JP2013543117A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013543117A5 JP2013543117A5 JP2013530750A JP2013530750A JP2013543117A5 JP 2013543117 A5 JP2013543117 A5 JP 2013543117A5 JP 2013530750 A JP2013530750 A JP 2013530750A JP 2013530750 A JP2013530750 A JP 2013530750A JP 2013543117 A5 JP2013543117 A5 JP 2013543117A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- sample
- epitope
- cancer
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 7
- 238000011319 anticancer therapy Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- YABJJWZLRMPFSI-UHFFFAOYSA-N 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine Chemical compound N=1C2=CC(OC=3C=C(N=CC=3)C=3NC(=CN=3)C(F)(F)F)=CC=C2N(C)C=1NC1=CC=C(C(F)(F)F)C=C1 YABJJWZLRMPFSI-UHFFFAOYSA-N 0.000 claims description 3
- 108020005544 Antisense RNA Proteins 0.000 claims description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 3
- DEZZLWQELQORIU-RELWKKBWSA-N GDC-0879 Chemical compound N=1N(CCO)C=C(C=2C=C3CCC(/C3=CC=2)=N\O)C=1C1=CC=NC=C1 DEZZLWQELQORIU-RELWKKBWSA-N 0.000 claims description 3
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 3
- 108020004459 Small interfering RNA Proteins 0.000 claims description 3
- 239000003184 complementary RNA Substances 0.000 claims description 3
- 229960003787 sorafenib Drugs 0.000 claims description 3
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 3
- 229960003862 vemurafenib Drugs 0.000 claims description 3
- -1 anti-BRAF antibody Substances 0.000 claims description 2
- 229960005395 cetuximab Drugs 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 238000004458 analytical method Methods 0.000 claims 4
- 230000027455 binding Effects 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 210000004408 hybridoma Anatomy 0.000 claims 3
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims 2
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 4
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38815810P | 2010-09-30 | 2010-09-30 | |
| US61/388,158 | 2010-09-30 | ||
| US201161503950P | 2011-07-01 | 2011-07-01 | |
| US61/503,950 | 2011-07-01 | ||
| PCT/EP2011/067092 WO2012042009A1 (en) | 2010-09-30 | 2011-09-30 | Means and methods for diagnosing cancer using an antibody which specifically binds to braf v600e |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013543117A JP2013543117A (ja) | 2013-11-28 |
| JP2013543117A5 true JP2013543117A5 (enExample) | 2015-10-01 |
| JP5893037B2 JP5893037B2 (ja) | 2016-03-23 |
Family
ID=44789447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013530750A Active JP5893037B2 (ja) | 2010-09-30 | 2011-09-30 | Ｂｒａｆｖ６００ｅに特異的に結合する抗体を使用する癌の診断のための手段及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9297812B2 (enExample) |
| EP (1) | EP2622348B1 (enExample) |
| JP (1) | JP5893037B2 (enExample) |
| CN (1) | CN103403550B (enExample) |
| AU (1) | AU2011310096B2 (enExample) |
| CA (1) | CA2813098C (enExample) |
| DK (1) | DK2622348T3 (enExample) |
| ES (1) | ES2554678T3 (enExample) |
| WO (1) | WO2012042009A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103172744B (zh) * | 2012-09-28 | 2016-01-13 | 武汉纽斯特生物技术有限公司 | 特异性识别B-Raf突变蛋白的单克隆抗体、制备方法及其应用 |
| JP6485854B2 (ja) * | 2014-09-24 | 2019-03-20 | 国立研究開発法人国立循環器病研究センター | 抗変異型プロテインｓ抗体、該抗体を含む診断用組成物、変異型ヒトプロテインｓの検出方法および該抗体を含むキット |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| JP6941688B2 (ja) * | 2017-06-29 | 2021-09-29 | コリア アドヴァンスド インスティテュート オブ サイエンス アンド テクノロジー | 神経節膠腫が誘導された動物モデルならびに神経節膠腫およびこれに関連する疾患の診断用組成物 |
| CN110183535A (zh) * | 2018-12-17 | 2019-08-30 | 南京基诺米医疗科技有限公司 | 鼠抗人braf v600e突变蛋白单克隆抗体制备及其免疫组化用途 |
| CN111285935B (zh) * | 2020-05-13 | 2020-09-11 | 方达医药技术(上海)有限公司 | 特异性检测braf基因突变的抗体及其在制备癌症检测试剂盒中的用途 |
| AU2021378815A1 (en) * | 2020-11-16 | 2023-06-29 | Agilent Technologies, Inc. | Chimeric anti-human braf v600e antibodies and methods for making and using them |
| WO2024090265A1 (ja) * | 2022-10-28 | 2024-05-02 | 株式会社biomy | 情報処理装置、情報処理方法及びプログラム |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6735531B2 (en) * | 1996-10-07 | 2004-05-11 | Lab Vision Corporation | Method and apparatus for automatic tissue staining |
| AU2003286447A1 (en) * | 2003-10-16 | 2004-06-06 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Treatments for inhibiting development and progression of nevi and melanoma having braf mutations |
| WO2007002811A2 (en) | 2005-06-29 | 2007-01-04 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for treating melanoma |
| US8034792B2 (en) | 2007-09-11 | 2011-10-11 | University Of Massachusetts | Insulin-like growth factor binding protein 7 for treatment of cancer |
| JP2009077712A (ja) | 2007-09-11 | 2009-04-16 | F Hoffmann La Roche Ag | Ｂ−Ｒａｆキナーゼ阻害剤に対する感受性についての診断試験 |
-
2011
- 2011-09-30 DK DK11767970.4T patent/DK2622348T3/en active
- 2011-09-30 JP JP2013530750A patent/JP5893037B2/ja active Active
- 2011-09-30 AU AU2011310096A patent/AU2011310096B2/en active Active
- 2011-09-30 WO PCT/EP2011/067092 patent/WO2012042009A1/en not_active Ceased
- 2011-09-30 EP EP11767970.4A patent/EP2622348B1/en active Active
- 2011-09-30 CA CA2813098A patent/CA2813098C/en active Active
- 2011-09-30 US US13/877,035 patent/US9297812B2/en active Active
- 2011-09-30 CN CN201180056079.4A patent/CN103403550B/zh active Active
- 2011-09-30 ES ES11767970.4T patent/ES2554678T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013543117A5 (enExample) | ||
| JP2015533788A5 (enExample) | ||
| US9846160B2 (en) | Ganglioside GD2 as a marker and target on cancer stem cells | |
| WO2012141844A3 (en) | Methods predicting risk of an adverse clinical outcome | |
| WO2022082073A2 (en) | Compositions and methods for muc18 targeting | |
| HUE030578T2 (en) | Use of Human Leukemia Inhibitor Antibody (LIF) and Antibodies to LIF to Treat Diseases Related to Unwanted Cell Proliferation | |
| WO2013078455A3 (en) | Proteomic identification of antibodies | |
| JP2013544493A5 (enExample) | ||
| WO2009019365A3 (fr) | Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal | |
| TW201529603A (zh) | α-烯醇化酶特異性抗體及其於癌症治療之應用 | |
| JP2020037571A (ja) | Ｔｍｃｃ３の阻害による、癌を抑制するための方法 | |
| JP2015519335A (ja) | 抗ｃ−Ｍｅｔ抗体 | |
| JP2013505938A5 (enExample) | ||
| CN112062851A (zh) | 靶向bcma嵌合抗原受体的抗体及其应用 | |
| US20160176936A1 (en) | Mps peptides and use thereof | |
| WO2012165926A3 (ko) | 항-ａｔｉｃ 자가면역항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물 | |
| US10584387B2 (en) | Detection of hepatitis delta virus (HDV) for the diagnosis and treatment of Sjögren's syndrome and lymphoma | |
| JP2022552000A (ja) | 抗コハク酸モノクローナル抗体およびヒト化抗コハク酸抗体 | |
| CN106957367B (zh) | 抗idh1 r132h抗体及其制备方法和用途 | |
| KR20170138466A (ko) | 새로운 igf-1r 항체 및 암의 진단을 위한 그의 용도 | |
| WO2020178313A1 (en) | New biomarkers and biotargets in renal cell carcinoma | |
| JP2012521745A5 (enExample) | ||
| EP3807315A2 (en) | Methods for improving response to anti-lif antibody treatment in individuals with cancer | |
| US20240210407A1 (en) | Compositions and methods for detecting and treating pathological fibroblast cells | |
| JP2011141279A (ja) | 抗ｉｇｆ−ｉｒ癌療法のためのバイオマーカー |